ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report)’s share price dropped 3.2% during trading on Thursday . The stock traded as low as $67.94 and last traded at $68.56. 51,634 shares were traded during trading, an increase of 37% from the average session volume of 37,809 shares. The stock had previously closed at $70.79.
ALPS Medical Breakthroughs ETF Stock Down 3.2%
The business has a 50 day simple moving average of $63.89 and a two-hundred day simple moving average of $56.41.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of SBIO. Exencial Wealth Advisors LLC increased its position in shares of ALPS Medical Breakthroughs ETF by 3.2% in the fourth quarter. Exencial Wealth Advisors LLC now owns 8,101 shares of the company’s stock worth $415,000 after purchasing an additional 248 shares during the last quarter. Royal Bank of Canada raised its stake in ALPS Medical Breakthroughs ETF by 2.8% in the fourth quarter. Royal Bank of Canada now owns 12,269 shares of the company’s stock valued at $628,000 after purchasing an additional 330 shares in the last quarter. Harbor Investment Advisory LLC bought a new stake in ALPS Medical Breakthroughs ETF during the second quarter valued at approximately $29,000. Steward Partners Investment Advisory LLC bought a new stake in ALPS Medical Breakthroughs ETF during the fourth quarter valued at approximately $26,000. Finally, Griffin Asset Management Inc. lifted its position in ALPS Medical Breakthroughs ETF by 1.9% during the fourth quarter. Griffin Asset Management Inc. now owns 30,699 shares of the company’s stock valued at $1,572,000 after purchasing an additional 564 shares during the last quarter.
ALPS Medical Breakthroughs ETF Company Profile
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.
Recommended Stories
- Five stocks we like better than ALPS Medical Breakthroughs ETF
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.
